CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
Recruiting now
Conditions studied: Non-Small Cell Lung Cancer
In brief
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.
Key facts
- Study ID
- NCT07413757
- Run by
- AstraZeneca
- People needed
- 590
- Starts
- 2026-03-02
- Expected to finish
- 2026-07-31
- Last updated by the study team
- 2026-07-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- The following inclusion criteria must be met in order to be enrolled in the stage 1:
- Patient:
- Provide informed consent
- 18 years or older
- Diagnosed with stage IV NSCLC
- Currently receiving or previously received 1L EGFR-TKI treatment
- Without communication barrier
- Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter
- Physician:
- Provide informed consent
- Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
- Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
- Holding the title of associate chief physician or higher
- The following inclusion criteria must be met in order to be enrolled in the stage 2:
- Patient:
- Provide informed consent
- 18 years or older
- Diagnosed with stage IV NSCLC
- Currently receiving or previously received 1L EGFR-TKI treatment
- Without communication barrier
- Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter
- Physician:
- Provide informed consent
- Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
- Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
You may not qualify if…
- Not applicable.
Where it is running
- Research Site — Chengdu, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.